Newark, DE, Dec. 29, 2025 (GLOBE NEWSWIRE) -- The term "best" reflects common consumer search phrasing and is used here…
Mexico: The New Hub for US Hair Transplants December 26, 2025 10:00 ET | Source: Capilea Mexico Tijuana, BC, Dec.…
PYLCLARI® provides solutions to a wider patient group across Poland where there is high demand and unmet need PARIS, Dec.…
- First patient in the world treated with Alpha DaRT® in the brain – - According to the National Brain…
In addition, the expansive elacestrant clinical development program updates reinforce its potential as a backbone endocrine therapy in combination settings, as…
93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large B-cell…
Selective Treg modulator gotistobart (BNT316/ONC-392) showed a reduction in the risk of death by more than half compared to standard…
Long-term OS follow-up analysis of JUPITER-02 demonstrates significantly better and clinically meaningful improvement with toripalimab plus chemotherapy as 1st-line treatment…
December 05, 2025 20:00 ET | Source: ORIC Pharmaceuticals Highly differentiated 1L preliminary systemic activity of 67% ORR and 100%…
December 05, 2025 01:00 ET | Source: ORIC Pharmaceuticals Systemic activity of 35% ORR in 2L+ patients, including in patients…